Article Versions Notes

Forsberg EMV, Riise R, Saellström S, Karlsson J, Alsén S, Bucher V, Hemminki AE, Olofsson Bagge R, Ny L, Nilsson LM, et al. Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. Cancers. 2023; 15(3):648. https://doi.org/10.3390/cancers15030648

Forsberg, Elin M. V., Rebecca Riise, Sara Saellström, Joakim Karlsson, Samuel Alsén, Valentina Bucher, Akseli E. Hemminki, Roger Olofsson Bagge, Lars Ny, Lisa M. Nilsson, and et al. 2023. "Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs" Cancers 15, no. 3: 648. https://doi.org/10.3390/cancers15030648

Forsberg, E. M. V., Riise, R., Saellström, S., Karlsson, J., Alsén, S., Bucher, V., Hemminki, A. E., Olofsson Bagge, R., Ny, L., Nilsson, L. M., Rönnberg, H., & Nilsson, J. A. (2023). Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. Cancers, 15(3), 648. https://doi.org/10.3390/cancers15030648